BPA for emflaza
Active Awarded Last action
- Contract number
- 36E79724A0007
- Awardee
-
PTC Therapeutics US, Inc. UEI RWWKLJ9LFHU9 Part of PTC Therapeutics, Inc.
- Awarding agency
-
National Acquisition Center
Headquarters, Department of Veterans Affairs
- Task orders
- 0
Award facts
- Opportunity
-
- VA797P12Q0002 Solicitation number
- Last date to order 86% complete
- IDV ceiling
- $12,500.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
This Blanket Purchase Agreement (BPA), awarded on March 9, 2024, to PTC Therapeutics US, Inc. (UEI: RWWKLJ9LFHU9), under parent company PTC Therapeutics, Inc., establishes a vehicle for the procurement of Emflaza, a pharmaceutical product. The BPA represents Exercise Option Year 2 of contract number 36E79724A0007 and operates under the Pharmaceuticals and Drugs master schedule (FSS-61-IB). The National Acquisition Center, a civilian federal agency, serves as the funding entity. The agreement is structured as a single-award BPA with no set-aside provisions applied, establishing a ceiling value of $12,500.00 and an ultimate completion date of March 14, 2027.
Emflaza is indicated for the treatment of Duchenne muscular dystrophy (DMD), a rare genetic disorder affecting muscle function, making this BPA's pharmaceutical procurement directly aligned with the federal government's healthcare and therapeutic supply requirements. The BPA vehicle facilitates streamlined acquisition of this specialized pharmaceutical through a pre-established pricing and delivery mechanism, reducing procurement lead times while ensuring continued access to this critical therapeutic agent. The relatively modest ceiling value reflects the nature of the BPA as an ongoing supply mechanism rather than a large-scale single procurement, allowing for flexible ordering quantities throughout the performance period while maintaining cost controls and standardized pricing terms established under the master schedule agreement.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 36E79724A0007?
36E79724A0007 was awarded to PTC Therapeutics US, Inc. by National Acquisition Center (Headquarters) on March 9, 2024.
How much is contract 36E79724A0007 worth?
36E79724A0007's own ceiling is $12,500.
Who can order from contract 36E79724A0007?
36E79724A0007 is a single award blanket purchase agreement. Only the awarding agency can place orders on it.
Is contract 36E79724A0007 under another contract?
Yes. 36E79724A0007 is a blanket purchase agreement under 36F79724D0074, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36E79724A0007 competed?
The extent of competition for 36E79724A0007 was full and open competition. The government received 1 offer.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV